Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...

Merck and Daiichi Sankyo, which were seeking approval of patritumab deruxtecan for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients Vandana Singh Mon, Apr 21, 2025, 8:05 AM 3 min read ...

As the second antibody-drug conjugate launched by Daiichi Sankyo and AstraZeneca, Datroway has a tough act to follow, coming on the heels of the companies’ emerging ADC cancer powerhouse Enhertu.

Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant and clinically meaningful improvement in main goal for its gastric or ...

Enhertu + pertuzumab showed significant PFS improvement vs. THP in HER2+ metastatic breast cancer in DESTINY-Breast09 trial. Interim OS data favored Enhertu combo; safety profile aligned with ...